Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.64 |
| ▸ | ACE | P12821 | 5/20 | 0.63 |
| ▸ | CPA1 | P15085 | 5/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanyl-Dl-Phenylalanine SCHEMBL27689824 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28142228 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28127119 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL2597740 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL4238049 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL893240 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28743188 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| Alanyl-Dl-Phenylalanine SCHEMBL28142226 | 1.00 | MME (0.65) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL29702065 | 0.97 | MME (0.61) | MMECTRB1ACECPA1ACE2 | |
| SCHEMBL10646215 | 0.94 | MME (0.58) | MMECTRB1ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143489-A2 | MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDE FRAGMENTS | ARCHER PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| US-5374551-A | Measurement of metabolism of alpha-methyl glucoside | BIOLOG, INC. (US) | 1994-12-20 | — | — | US | claimed |
| US-12577274-B2 | Manufacture of glucagon peptides | BACHEM HOLDING AG (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20210122782-A1 | MANUFACTURE OF GLUCAGON PEPTIDES | BACHEM HOLDING AG (CH) | 2021-04-29 | — | — | US | disclosed |
| US-10690635-B2 | Purification of glucagon-like peptide 1 analogs | BACHEM HOLDING AG (CH) | 2020-06-23 | — | — | US | disclosed |
| US-20190113483-A1 | PURIFICATION OF GLUCAGON-LIKE PEPTIDE 1 ANALOGS | BACHEM HOLDING AG (CH) | 2019-04-18 | — | — | US | disclosed |
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| CN-106565822-A | Preparation method for chiral L-alanyl-phenylalanine | 湖北泓肽生物科技有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106565822-A | Preparation method for chiral L-alanyl-phenylalanine | 湖北泓肽生物科技有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106565822-A | Preparation method for chiral L-alanyl-phenylalanine | 湖北泓肽生物科技有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-8981137-B2 | Method for producing a concentrate of eicosapentaenoic and docosahexaenoic acids | GOLDEN OMEGA S.A. (CL) | 2015-03-17 | — | — | US | disclosed |
| US-20140005425-A1 | METHOD FOR PRODUCING A CONCENTRATE OF EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACIDS | GOLDEN OMEGA S.A. (CL) | 2014-01-02 | — | — | US | disclosed |
| US-8586772-B2 | Method for producing a concentrate of eicosapentaenoic and docosahexaenoic acid esters | GOLDEN OMEGA S.A. (CL) | 2013-11-19 | — | — | US | disclosed |
| WO-2013123403-A1 | THERANOSTICS PLATFORM AND METHODS OF USE | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20120083616-A1 | METHOD FOR PRODUCING A CONCENTRATE OF EICOSAPENTAENOIC AND DOCOSAHEXAENOIC ACID ESTERS | GOLDEN OMEGA S.A. (CL) | 2012-04-05 | — | — | US | disclosed |
| WO-2011026091-A1 | IMIDAZOPYRIDAZINE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-1996007407-A1 | METHODS OF PRODUCING CARDIOTONIC EFFECT AND IMPROVING CARDIAC CONTRACTILE FUNCTION BY ADMINISTRATION OF CARNOSINE | WAKE FOREST UNIVERSITY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0081122-A1 | Carrier tripeptides with antifungal activity | Helopharm W. Petrik GmbH & Co.KG. (DE) | 1983-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577274-B2 | Manufacture of glucagon peptides | IAPP, GLP1R, GCG | MME 1328/4885CTRB1 443/4885ACE 1821/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MME 1953/4885CTRB1 2442/4885ACE 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.